// App-Quantinova.ai

OP0034 (2021) : STP938, A NOVEL, POTENT AND SELECTIVE INHIBITOR OF CTP SYNTHASE 1 (CTPS1) DEMONSTRATES EFFICACY IN RODENT MODELS OF INFLAMMATION AND ARTHRITIS

Researchers

Presenter

  • H. Asnagli

Principal Investigators

  • A. Novak

  • R. Lane

  • N. Minet

  • P. George

  • S. Latour

  • A. Fischer

  • T. Bourne

  • A. Parker

Medical Centers

  • Step Pharma, Pharmacology, Archamps, France

  • Sygnature Discovery, Discovery Building-Biocity Building, Nottingham, United Kingdom

  • Institut Imagine, Laboratory of Lymphocyte Activation & EBV Susceptibility, INSERM-U1163, Paris, France

  • Independent consultant, Drug Discovery & Development, Paris, France

  • Gamut, Therapeutics, Paris, France

  • INSERM-U1163, AP-HP, Paris, France

  • Milvuswood, Consultancy, High Wycombe, United Kingdom

Locations

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

Biomarkers

  • Peripheral blood mononuclear cell

  • Immunoglobulin G

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved